Pfizer settles Protonix patent case for $2.15B

Two generic drugmakers will pay $2.15 billion to Pfizer and Takeda Pharmaceutical to settle a patent fight over the heartburn treatment Protonix.

Teva Pharmaceutical Industries Ltd., one of the world's largest generic drugmakers, will pay $1.6 billion, while India's Sun Pharmaceutical Industries Ltd. will pay $550 million for selling their versions of Protonix before the protecting the drug expired.

., based in New York, said Wednesday that it will receive 64 percent of the settlement proceeds.

A jury had decided in 2010 that the patent protecting Protonix was valid, and the U.S. District Court for the District of New Jersey then upheld that decision. The companies reached their settlement shortly after the start of a federal trial to determine damages.

Its lawsuit aimed to recover some of the money lost after Protonix started competing with cheaper . Drugmaker Nycomed had developed Protonix before that company was purchased by Japan's Takeda Pharmaceutical Co. Nycomed had licensed Protonix to Wyeth, which has since purchased.

Nycomed had said U.S. sales for the drug reached $1.9 billion in 2007 but tumbled significantly afterward.

Teva had started selling its of Protonix in December 2007. Sun then launched its own version in early 2008 before the drug's U.S. patent expired in 2011.

Teva and Sun had used a tactic called an "at-risk ," meaning they started selling their versions before the patents on the original expired. They hoped to either get the patents overturned in court or reach a settlement that would allow them to start selling their products before the patents ran out.

Teva, based in Israel, said it expects to incur a second-quarter charge of about $930 million tied to the settlement.

Shares of Pfizer rose 34 cents to $28.76 in Wednesday morning trading, while U.S.-traded shares of Teva fell 27 cents to $39.56.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Pfizer painkiller gets longer patent protection (Update)

Mar 05, 2013

Drugmaker Pfizer Inc. said Tuesday that a new patent on one of its top drugs, anti-inflammatory painkiller Celebrex, extends its U.S. patent protection by 18 months, potentially bringing the company a few billion dollars ...

Canada high court voids Pfizer's Viagra patent

Nov 08, 2012

Canada's top court on Thursday stripped Pfizer of its patent for Viagra, saying the pharmaceutical giant failed in the patent to identify the active compound in the drug.

Retailers sue Pfizer, charge generic Lipitor delay

Jul 07, 2012

(AP) — Five large U.S. drug and grocery chains are suing Pfizer Inc. and a second drugmaker, alleging they conspired to delay sales of cheap generic versions of the blockbuster cholesterol drug Lipitor.

High court weighs drug companies' generics policy

Mar 25, 2013

(AP)—The Supreme Court is struggling with whether it should stop pharmaceutical corporations from paying generic drug competitors to delay releasing their cheaper versions of brand-name drugs.

Court: Can drug companies pay to delay generics?

Mar 24, 2013

(AP)—Federal regulators are pressing the Supreme Court to stop big pharmaceutical corporations from paying generic drug competitors to delay releasing their cheaper versions of brand-name drugs. They argue ...

Recommended for you

Ebola vaccine not before late 2016: GSK researcher

Oct 17, 2014

An Ebola vaccine by British pharmaceuticals giant GlaxoSmithKline may not be ready for commercial use until late 2016 and should therefore not be seen as the "primary answer" to the current outbreak, a company researcher ...

Chimerix gets FDA OK to test drug for Ebola

Oct 17, 2014

(AP)—A North Carolina drugmaker plans to test its experimental antiviral drug in patients who have Ebola, after getting authorization from regulators at the Food and Drug Administration.

Esbriet, ofev approved to treat deadly lung disease

Oct 16, 2014

(HealthDay)—Two new drugs have been approved by the U.S. Food and Drug Administration to treat progressive lung scarring from an uncertain cause, medically called idiopathic pulmonary fibrosis (IPF).

FDA weighs removing bolded warning from Chantix

Oct 14, 2014

(AP)—The Food and Drug Administration will ask a panel of experts later this week whether a bold-letter warning on the anti-smoking drug Chantix should be removed based on company-supported evidence that the drug does not ...

Drug-coated balloon catheter approved

Oct 13, 2014

(HealthDay)—The first drug-coated balloon catheter designed to clear narrowed or blocked arteries in the thigh and knee has been approved by the U.S. Food and Drug Administration.

User comments